<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314181</url>
  </required_header>
  <id_info>
    <org_study_id>M15-654</org_study_id>
    <secondary_id>2017-002099-26</secondary_id>
    <nct_id>NCT03314181</nct_id>
  </id_info>
  <brief_title>A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib
      combination therapy to evaluate safety, tolerability, and efficacy of these combinations in
      participants with relapsed or refractory multiple myeloma. The study will consist of 2
      distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R)
      multiple myeloma who will receive venetoclax in combination with daratumumab and
      dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will
      receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd).

      Each Part will be initiated with a dose-escalation phase. During the open-label, escalation
      phases, increasing doses of venetoclax with fixed doses of daratumumab and dexamethasone
      (Part 1a) or daratumumab, bortezomib, and dexamethasone (Part 2a) will be administered. The
      dose-escalation phases will be followed by either a randomized, and blinded (Part 1b)
      expansion phase or single-arm and open-label (Part 2b) expansion phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Objective Response Rate (ORR)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>ORR is defined as the proportion of participants with documented partial response (PR) or better based on International Myeloma Working Group (IMWG) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Number of Participants with Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Adverse events occurring following Cycle 1 and evaluated by the Investigator and the sponsor; events that are considered to have a reasonable possibility of relationship to the administration of venetoclax, daratumumab, bortezomib, or dexamethasone, which cannot be attributed by the investigator to a clearly identifiable cause such as disease progression, concurrent illness, or concomitant medication, will be considered a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants with Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Up to Day 21</time_frame>
    <description>Adverse events occurring following Cycle 1 and evaluated by the Investigator and the sponsor; events that are considered to have a reasonable possibility of relationship to the administration of venetoclax, daratumumab, bortezomib, or dexamethasone, which cannot be attributed by the investigator to a clearly identifiable cause such as disease progression, concurrent illness, or concomitant medication, will be considered a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Complete Response (CR)</measure>
    <time_frame>Up to 5 months</time_frame>
    <description>CR is defined as the proportion of participants with documented response of CR or better (stringent complete response [sCR] or CR) based on IMWG criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR (Part 2b VenDVd Expansion)</measure>
    <time_frame>UP to 3 months</time_frame>
    <description>ORR is defined as the proportion of participants with a documented response PR or better based on IMWG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough) of Daratumumab</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Observed plasma concentration at trough (Ctrough) of Daratumumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Daratumumab</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of daratumumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>TTP is defined as the number of days from the date of the first dose of study drug (Arms A, D and E) or date of randomization (Arms B and C) to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>DOR is defined as the number of days from the participant's date of first documented response (PR or better) to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the number of days from the date of the first dose of study drug (for Arms A, D and E) or date of randomization (for Arms B and C) to the date of the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very Good Partial Response or Better Response Rate (VGPR)</measure>
    <time_frame>Up to 5 months</time_frame>
    <description>VGPR or better response rate is defined as the proportion of participants with documented VGPR or better (sCR, CR. or VGPR) based on IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Venetoclax</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 of Venetoclax</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) over the dose interval (AUC0-24) of venetoclax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Venetoclax</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Time to Cmax (Tmax) of Venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>MRD negativity in bone marrow aspirates is defined at 10^-5 threshold as assessed by next generation sequencing (NGS) in participants at the time of suspected CR/sCR, and at 6 and 12 months post confirmation of CR/sCR for participants who maintained this response.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cancer - Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm B, Part 1b: VenDd Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at various doses administered orally QD in combination with daratumumab (16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 8, Days 1, 2, 4, 5, 8, 9, 11, and 12, 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C, Part 1b : Placebo + Dd Expansion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally QD in combination with daratumumab (16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Part 1a: VenDd Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 8, Days 1, 2, 4, 5, 8, 9, 11, and 12, 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol) Cycle 9+.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral or intravenous</description>
    <arm_group_label>Arm A, Part 1a: VenDd Dose Escalation</arm_group_label>
    <arm_group_label>Arm B, Part 1b: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm C, Part 1b : Placebo + Dd Expansion</arm_group_label>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Arm A, Part 1a: VenDd Dose Escalation</arm_group_label>
    <arm_group_label>Arm B, Part 1b: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm C, Part 1b : Placebo + Dd Expansion</arm_group_label>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Oral</description>
    <arm_group_label>Arm A, Part 1a: VenDd Dose Escalation</arm_group_label>
    <arm_group_label>Arm B, Part 1b: VenDd Dose Expansion</arm_group_label>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
    <other_name>ABT-199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Arm C, Part 1b : Placebo + Dd Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Subcutaneous (preferred) or intravenous</description>
    <arm_group_label>Arm D, Part 2a: VenDVd Dose Escalation</arm_group_label>
    <arm_group_label>Arm E, Part 2b: VenDVd Dose Expansion</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;= 2.

          -  Participant has relapsed or refractory multiple myeloma with documented evidence of
             progression that occurred during or after the participant's last treatment regimen
             based on investigator's determination of International Myeloma Working Group (IMWG)
             criteria.

          -  Measurable disease confirmed by central lab at Screening, defined by at least 1 of the
             following:

               1. Serum M-protein &gt;= 1.0 g/dL (&gt;= 10 g/L), OR

               2. Urine M-protein &gt;= 200 mg/24 hours, OR

               3. Serum free light chain (FLC) &gt;= 10 mg/dL, provided serum FLC ratio is abnormal in
                  participants who do not have measurable disease by Serum Protein Electrophoresis
                  (SPEP) or Urine Protein Electrophoresis (UPEP) criteria.

          -  Participant has received previous multiple myeloma treatment as defined in the
             protocol for Part 1 and Part 2 of this study.

          -  Bone marrow aspirate samples have been collected.

          -  To qualify for Part 1, the participant must be t(11;14) positive as determined by an
             analytically validated Fluorescent In Situ Hybridization (FISH) assay per central
             laboratory testing.

          -  Participants must have adequate hematologic, renal and hepatic function.

        Exclusion Criteria:

          -  Previous treatment with venetoclax or other B-Cell Lymphoma 2 (BCL-2) inhibitor OR
             previous treatment with daratumumab or other anti-CD38 therapy.

          -  For participants in Part 2:

               1. Participant is refractory to any proteasome inhibitor, defined as progression on
                  or within 60 days of the last dose of a proteasome inhibitor-containing regimen.

               2. Participant has had prior treatment with proteasome inhibitor within 60 days
                  prior to first dose of study drug.

          -  Treatment with anti-myeloma chemotherapy, radiotherapy, biological, immunotherapy or
             an investigational therapy, including targeted small molecule agents within 2 weeks or
             5 half-lives (whichever is longer and/or applicable) before first dose.

          -  Treatment with anti-myeloma monoclonal antibodies within 6 weeks prior first dose.

          -  Recent corticosteroid therapy at a cumulative dose equivalent to &gt;= 140 mg of
             prednisone or a single dose equivalent to &gt;= 40 mg/day of dexamethasone within 2 weeks
             prior the first dose of study drug.

          -  Known meningeal involvement of multiple myeloma.

          -  Significant history of medical conditions as listed in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Inst, US</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bend Memorial Clinic</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science Universi</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern Health</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincents Hosp Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Ctr</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGill Univ HC</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen Ø</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <state>Midtjylland</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Odense Universitets Hospital</name>
      <address>
        <city>Odense C</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sygehus Lillebaelt - Vejle Syg</name>
      <address>
        <city>Vejle</city>
        <state>Syddanmark</state>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu - CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Bretonneau - CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Technische Universitat Munchen</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>t(11;14) positive relapsed/refractory (R/R) multiple myeloma</keyword>
  <keyword>Non-refractory Relapsed Multiple Myeloma</keyword>
  <keyword>Non-refractory Refractory Multiple Myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

